Theodore Roosevelt, MD
Endocrinology, Diabetes & Metabolism · Boise, IDNPI 1699754697
Payments from drug & device makers
Across 566 payments — averaging $114.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$27K
- Johnson & Johnson$13K
- Novo Nordisk$9K
- AbbVie$7K
- Corcept Therapeutics$4K
- Abbott$691
- plus $4K from 26 others
What the payments were for
- Consulting fees$9,94515%
- Speaking & faculty fees$42,79566%
- Travel & lodging$2,9835%
- Food & beverage$8,80814%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 72 | $26,640 |
| Johnson & Johnson | 25 | $12,868 |
| Novo Nordisk | 137 | $9,421 |
| AbbVie | 32 | $6,916 |
| Corcept Therapeutics | 60 | $4,416 |
| Abbott | 22 | $691 |
| Amgen(2 entities) | 19 | $532 |
| Lilly USA, LLC | 38 | $494 |
| Antares Pharma, Inc. | 26 | $355 |
| Novartis | 25 | $338 |
| Sanofi-aventis U.S. LLC | 24 | $337 |
| Boehringer Ingelheim | 13 | $299 |
| Xeris Pharmaceuticals, Inc. | 12 | $272 |
| Esperion Therapeutics, Inc. | 14 | $149 |
| Recordati_rare_diseases_inc. | 5 | $115 |
| Dexcom, Inc. | 5 | $90 |
| Bayer | 5 | $89 |
| Insulet Corporation | 4 | $85 |
| Merck | 5 | $73 |
| IBSA Pharma Inc. | 3 | $53 |
| Halozyme Inc | 3 | $43 |
| Ascendis Pharma Endocrinology Inc | 2 | $38 |
| Pfizer | 2 | $33 |
| Medtronic | 2 | $33 |
| Amarin Pharma, Inc. | 2 | $31 |
| Nestle Healthcare Nutrition Inc. | 2 | $31 |
| Aimmune Therapeutics, Inc. | 2 | $31 |
| Amryt Pharma Holdings Ltd | 1 | $26 |
| Acella Pharmaceuticals, LLC | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Averitas Pharma Inc. | 1 | $13 |
| Tandem Diabetes Care, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$25,632
- INVOKANA$12,524
- Victoza$8,334
- Synthroid$6,625
- Korlym$3,537
- FreeStyle Libre 2$120
- FreeStyle Libre$112
- JARDIANCE$111
- TEPEZZA$105
- Repatha$103
How this compares
Too few endocrinology, diabetes & metabolism providers in Idahoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 130 | $175,211 |
| OzempicSemaglutide | 90 | $128,645 |
| Tresiba Flextouch U-200Insulin Degludec | 66 | $102,694 |
| JardianceEmpagliflozin | 77 | $95,609 |
| Tresiba Flextouch U-100Insulin Degludec | 87 | $57,171 |
| Humalog Kwikpen U-200Insulin Lispro | 26 | $44,796 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 65 | $44,440 |
| TrulicityDulaglutide | 41 | $43,260 |
| CreonLipase/Protease/Amylase | 12 | $36,019 |
| Repatha SyringeEvolocumab | 30 | $36,010 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $30,162 |
| Xigduo XrDapaglifloz Propaned/Metformin | 31 | $29,571 |
| JanuviaSitagliptin Phosphate | 18 | $27,091 |
| Repatha SureclickEvolocumab | 41 | $25,543 |
| KerendiaFinerenone | 14 | $23,746 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $26,640 | $175,211130 claims |
| Novo NordiskOzempic | $9,421 | $128,64590 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $299 | $107,73692 claims |
| Lilly USA, LLCTrulicity, Humalog | $494 | $45,94454 claims |
| AbbVieCreon, Synthroid | $6,916 | $45,407111 claims |
| MerckJanuvia | $73 | $27,09118 claims |
| BayerKerendia | $89 | $23,74614 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $337 | $15,09218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology, diabetes & metabolism providers in Idahoon file to place this against a meaningful peer group, so we don't.
Other endocrinology, diabetes & metabolism in Boise
- Julie FooteBoise$8K
- Shanaz SikderBoise$3K
- Richard ChristensenBoise$2K
- Robert MinnsBoise$644
- David LiljenquistIdaho Falls$16.8M
- Carl VanceIdaho Falls$3.5M
- John LiljenquistIdaho Falls$554K
- Robert EnnisMeridian$69K
- Lynn Ge-ZerbeMeridian$9K
- Katy ConnleyEagle$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.